



Pharmacolog announces the appointment of Anders Hedlund as interim CEO

The Board has decided to appoint Anders Hedlund as interim CEO of the company. He replaces thereby Lars Gusch who will step down to pursue external opportunities as announced in an earlier press release. The replacement of CEO will be in effect from May 1, 2024.

Anders Hedlund is currently the CEO of Nolsterby Invest AB, the largest shareholder in Pharmacolog. Nolsterby Invest AB is an investment company in the healthcare sector and has been invested in Pharmacolog since 2017. Since 2023, Anders Hedlund is also a current Board Member of Pharmacolog, a position he plans to maintain.

Erik Hedlund, Chairman of the Board and main owner of Pharmacolog: "We are in a transformational process to become a serial acquirer within the healthcare sector. There is a lot of work to be done although we have made progress during the quarter by, for instance, divesting the Druglog product line. Recently, we also announced our intention to change the name of the company. Anders Hedlund's main task will be to lay the ground for the new business direction. His extensive experience and network in the healthcare and financial industry make him suitable for this task."

This is a translation of the Swedish version of the press release. In case of any discrepancies, the Swedish version prevails.

For more information contact:

Erik Hedlund, Chairman

Email: erik.hedlund@nolsterbyinvest.se
Phone: +46 70-382 08 41

About Pharmacolog

Pharmacolog (proposed name change to Perpetua Medical AB (publ)) is a medical technology company, headquartered in Uppsala, Sweden. The company's shares (ticker PHLOG B) are traded on Nasdaq First North Stockholm.

The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, [WasteLog™](#) and [Pharmacolog Dashboard™](#).

Further information regarding the company is available at <http://pharmacolog.com/>.

The company's Certified Adviser is Mangold Fondkommission AB.